- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03466970
Plasmablast Detection From IgG4-Related Disease Patients
Study Overview
Status
Conditions
Detailed Description
IgG4-related disease (IgG4-RD) is an immune-mediated, fibro-inflammatory disease that leads to tissue damage, organ dysfunction and, if untreated, to organ failure. The disease can affect almost any anatomic location, but the sites involved most commonly are the pancreas, salivary glands, orbital adnexa, lymph nodes, and retroperitoneum. IgG4-RD, typically diagnosed among individuals who are middle-aged, is characterized by a male predominance except with regard to organs of the head and neck (e.g., the salivary glands and orbits), where the gender distribution is approximately equal. The epidemiology of IgG4-RD remains poorly understood because of its recognition only recently as a multi-organ disease. However, IgG4-RD accounts for many conditions once regarded as disparate, single-organ disorders.
The current gold standard for the diagnosis of IgG4-RD is the identification of characteristic histology and immunohistochemistry features through biopsy. These pathology features are consistent across the full range of organs affected by IgG4-RD. However, histopathologic variation can occur according to the stage of the lesion; that is, longstanding disease may be predominately fibrotic and a cellular. Confirming the diagnosis of IgG4-RD in such cases can be difficult. Moreover, IgG4-RD organ pathology and IgG4-RD mimickers, such as granulomatosis with polyangiitis (formerly Wegener's), sarcoidosis, histiocytosis, and malignancies (e.g., lymphoma and adenocarcinoma of the pancreas), may share similar features including an IgG4-positive plasma cell infiltrate. Reliance upon serum IgG4 concentrations to diagnose IgG4-RD is similarly problematic because both the specificity and positive predictive value of serum IgG4 concentrations are poor.
Plasmablasts, derived from the B-cell lineage and characterized as CD19lowCD20-CD38+CD27+, comprise a stage intermediate between activated B-cells and plasma cells. Plasmablasts are generally rare in the peripheral blood of healthy individuals, but expansions are observed briefly during responses to infection or vaccination. In contrast, in the setting of autoimmunity and persistent self-antigen(s), plasmablasts can circulate for prolonged periods.
Circulating plasmablasts have been described previously in inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, and multiple myeloma. Recently, several studies identified plasmablsts in IgG4-RD both as a diagnostic tool and as an indicator of response to treatment
2. Aim
The purpose of our study is to evaluate the method of plasmablast measurement in peripheral blood of IgG4-RD patients, for diagnosis and follow-up on disease progression and response to treatment. This document will outline the collection, processing and testing procedures for measuring plasmablasts from IgG4-RD patients.
3. Plasmablast source
Plasmablasts will be isolated from peripheral blood derived from patients and normal donors who consent to participate in the study. Blood samples will be drawn by a physician or accredited nurse, transferred to the research lab in order to separate PMBCs, which will be stained for CD19lowCD20-CD38+CD27+ markers and measured by flow cytometry (FACS) located at the hematology lab
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: yael Eizikovits, Mrs
- Phone Number: 972-09-7471936
- Email: yael.eizikovits@clalit.org.il
Study Locations
-
-
-
Kfar Saba, Israel, 44281
- Yael Eizikovits
-
Kfar-saba, Israel
- Meir health center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients that obtaining their written consent.
- Patients above the age of 18 and referred to the Rheumatology clinic or Internal Medicine E Department at the Meir Medical Center for investigation or treatment of IgG4-RD will be candidates to participate in the study.
- Patients at their primary diagnosis or follow up will be eligible for this study.
Exclusion Criteria:
- Patient that not diagnosed before with IgG4.
- patients that does not referred to the Rheumatology clinic or Internal Medicine E Department at the Meir Medical Center.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
IgG4 patient
20 samples of IgG4 patients
|
healthy donors
20 healthy donors
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
plasmablast measurement in peripheral blood of IgG4-RD patients
Time Frame: 1 year
|
Plasmablasts will be isolated from peripheral blood derived from patients and normal donors who consent to participate in the study.
Blood samples will be drawn by a physician or accredited nurse, transferred to the research lab in order to separate PMBCs, which will be stained for CD19lowCD20-CD38+CD27+ markers and measured by flow cytometry (FACS) located at the hematology lab.
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yair Levy, prof, head of internal medicin E
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0217-17
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on IgG4-related Disease
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers Squibb; Rho Federal Systems Division, Inc.; Autoimmunity Centers...TerminatedIgG4 Related Disease | IgG4-RDUnited States
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruiting
-
Meir Medical CenterCompletedUndiagnosed IgG4 Related DiseasesIsrael
-
Zenas BioPharma (USA), LLCRecruitingIgG4 Related DiseaseUnited States, Korea, Republic of, Spain, Japan, France, Poland, Taiwan, Italy, United Kingdom, Argentina, Netherlands, Turkey, Hong Kong, Sweden, Hungary, Germany, Mexico
-
Matthew C. BakerStanford UniversityRecruiting
-
AmgenActive, not recruitingIgG4 Related DiseasePoland, Spain, United States, Argentina, Australia, Canada, China, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Sweden, Turkey, United Kingdom
-
Beijing Friendship HospitalNot yet recruiting
-
Xencor, Inc.Massachusetts General HospitalCompleted